Last reviewed · How we verify
Stemis™
At a glance
| Generic name | Stemis™ |
|---|---|
| Sponsor | Ji Yan Biomedical Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Safety and Tolerability of Intravenous Stemis™ in Elderly Subjects With Mild to Moderate Frailty Syndrome (PHASE1)
- Microvascular Recovery With Ultrasound in Myocardial Infarction (MRUSMI) Post PCI Trial (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Stemis™ CI brief — competitive landscape report
- Stemis™ updates RSS · CI watch RSS
- Ji Yan Biomedical Co., Ltd. portfolio CI